Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 02 01:56PM ET
0.8970
Dollar change
-0.0332
Percentage change
-3.57
%
Index- P/E- EPS (ttm)-0.27 Insider Own3.98% Shs Outstand77.07M Perf Week-5.98%
Market Cap69.13M Forward P/E- EPS next Y-0.33 Insider Trans0.00% Shs Float74.01M Perf Month-22.00%
Income-20.31M PEG- EPS next Q-0.08 Inst Own1.62% Short Float3.58% Perf Quarter-5.60%
Sales0.00M P/S- EPS this Y-0.20% Inst Trans-6.67% Short Ratio5.80 Perf Half Y-16.17%
Book/sh0.09 P/B10.31 EPS next Y-7.02% ROA-78.05% Short Interest2.65M Perf Year-38.14%
Cash/sh0.19 P/C4.76 EPS next 5Y- ROE-144.22% 52W Range0.84 - 1.53 Perf YTD-33.56%
Dividend Est.- P/FCF- EPS past 5Y18.01% ROI-278.00% 52W High-41.37% Beta1.63
Dividend TTM- Quick Ratio2.99 Sales past 5Y0.00% Gross Margin- 52W Low6.77% ATR (14)0.07
Dividend Ex-Date- Current Ratio2.99 EPS Y/Y TTM28.43% Oper. Margin0.00% RSI (14)33.95 Volatility5.30% 6.00%
Employees27 Debt/Eq0.12 Sales Y/Y TTM- Profit Margin- Recom1.12 Target Price4.93
Option/ShortNo / Yes LT Debt/Eq0.09 EPS Q/Q14.34% Payout- Rel Volume2.35 Prev Close0.93
Sales Surprise- EPS Surprise-16.98% Sales Q/Q- EarningsNov 12 BMO Avg Volume456.82K Price0.90
SMA20-12.19% SMA50-17.61% SMA200-14.83% Trades Volume749,269 Change-3.57%
Date Action Analyst Rating Change Price Target Change
Oct-06-22Initiated Maxim Group Buy $3
Feb-17-21Initiated H.C. Wainwright Buy $15
Today 10:18AM
Nov-14-24 08:00AM
Nov-13-24 02:08AM
Nov-12-24 07:00AM
Nov-11-24 07:00AM
07:32AM Loading…
Oct-15-24 07:32AM
Oct-07-24 11:21AM
Oct-04-24 09:00AM
07:00AM
Sep-24-24 09:15AM
Sep-20-24 11:08AM
09:00AM
Sep-19-24 12:08PM
07:00AM
Sep-06-24 08:00AM
04:37PM Loading…
Aug-12-24 04:37PM
07:45AM
Aug-02-24 07:00AM
Aug-01-24 04:01PM
Jul-24-24 07:00AM
Jun-27-24 03:28PM
07:00AM
Jun-24-24 07:00AM
Jun-21-24 06:53AM
Jun-20-24 05:26PM
10:00AM
08:45AM
07:26AM
Jun-19-24 01:09PM
Jun-12-24 10:22AM
09:55AM Loading…
Jun-04-24 09:55AM
Jun-03-24 09:17AM
May-28-24 01:24PM
May-24-24 12:16PM
08:45AM
07:00AM
May-23-24 11:51AM
May-17-24 12:50PM
May-16-24 07:00AM
May-15-24 11:14AM
08:03AM
07:00AM
May-10-24 04:35PM
May-09-24 08:59PM
04:21PM
04:01PM
12:15PM
10:26AM
08:08AM
07:00AM
May-08-24 07:00AM
May-03-24 12:15PM
Apr-30-24 10:30AM
07:00AM
Apr-25-24 07:00AM
Apr-11-24 09:15AM
07:00AM
Apr-02-24 07:00AM
Mar-14-24 08:45AM
Mar-10-24 08:36AM
Mar-07-24 09:55PM
04:01PM
Mar-06-24 08:00AM
Mar-05-24 08:30AM
07:00AM
Mar-04-24 07:00AM
Feb-28-24 07:00AM
Feb-15-24 08:00AM
Feb-14-24 08:30AM
07:00AM
Feb-07-24 08:55AM
Jan-09-24 10:25AM
07:00AM
Jan-04-24 07:00AM
Dec-07-23 07:00AM
Nov-29-23 10:45AM
Nov-09-23 08:45AM
07:00AM
06:30AM
Nov-05-23 02:29PM
Nov-03-23 12:03PM
07:00AM
Oct-23-23 09:50AM
08:45AM
07:05AM
07:00AM
Oct-20-23 10:31AM
07:00AM
Oct-16-23 07:00AM
Oct-13-23 09:00AM
Oct-11-23 09:00AM
Sep-26-23 08:00AM
Sep-19-23 07:00AM
Sep-07-23 09:22AM
Sep-06-23 07:00AM
Aug-21-23 07:00AM
Aug-17-23 09:35AM
Aug-14-23 07:00AM
Aug-08-23 08:50AM
Aug-04-23 07:05AM
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.